Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
November 6, 2006
- Sixteen Genes that Predict Therapeutic Results Discovered
November 6, 2006
- There Will Be No NHI Price Revision Next April
November 6, 2006
- 8th Annual Meeting of the Japan Osteoporosis Society
November 6, 2006
- Price Agreement Rate Was 46.8% with Med. Institutions as of July
November 6, 2006
- Recommendation Grades of Drugs to Treat Osteoporosis Included in 2006 GL
November 6, 2006
- 24 New Drugs Approved
November 6, 2006
- R&DNEWS IN BRIEF
November 6, 2006
- SEMINAR
November 6, 2006
- OPINION
November 6, 2006
- MD Devices, Diagnostics at Chuikyo
November 6, 2006
- NEW PRODUCTS
November 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 6, 2006
- Japan-US Conference on Drug Review and Safety Wrapped Up
October 30, 2006
- Health Economics Forum Japan Symposium
October 30, 2006
- JPMA Expects Promotion of Innovation by Abe Cabinet: Mr Yamabe
October 30, 2006
- TOPICS AstraZeneca to Support Aging and Neglected Villages
October 30, 2006
- Korosho to Set Up Study Group to Discuss Measures to Eliminate "Drug Lag"
October 30, 2006
- Family History of Lung Cancer Doubles the Risk: Study
October 30, 2006
- Celecoxib Recommended for Approval
October 30, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…